- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04731363
Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion (COSETTE)
The principal goal for the study is to examine whether ingestion of a beverage containing artificial sweeteners alters in vitro platelet aggregation.
Because of the increasing number of cardiometabolic diseases, such as diabetes mellitus, in the population, the use of artificial sweeteners to replace free sugars has been gaining popularity. Two popular artificial sweeteners are erythritol and xylitol. Erythritol and xylitol are both naturally occurring polyols found in fruits and vegetables. They are potent artificial sweeteners with a higher sweetening intensity and lower calorie content than table sugar.
Previous research has shown that the higher levels of sugar alcohols, like those used as artificial sweeteners, in the blood are related to a higher risk of cardiovascular complications, like heart attacks and strokes, and death. This may be because higher levels of sugar alcohols in one's blood may increase the activity of platelets, which would then increase the risk of heart attack and stroke. The investigators therefore want to find if consuming a single beverage that contains an artificial sweetener can raise the levels of sugar alcohols in the blood and if it can alter platelet function or aggregation.
Study Overview
Status
Conditions
Detailed Description
The purpose of this study is to examine if drinking a single beverage that contains an artificial sweetener can perceptibly alter the activity of platelets in the body. Platelets are a component of blood that are primarily responsible for helping to stop bleeding and repair damaged blood vessels by grouping together, a process known as aggregation, to form clots.
Artificial sweeteners are popular because they have a lower calorie content than table sugar while still making food and beverages sweet. Their use as a sugar substitute is especially attractive for people with heart disease or diabetes, or for people who are trying to lose weight.
Two popular artificial sweeteners are erythritol and xylitol. Erythritol and xylitol are both naturally occurring polyols, also called sugar alcohols, found in fruits and vegetables. They are potent artificial sweeteners with a higher sweetening intensity and lower calorie content than table sugar.This makes them attractive for the use as sugar substitutes or alternatives, particularly for patients with type 2 diabetes.
Up to now, there is no prospective data available about polyols with respect to their impact on event outcomes in cardiovascular patients, despite their extensive use in the food industry. Moreover, little is known about plasma levels and metabolic changes following food intake of artificial sweeteners, in particular polyols.
The investigators have previously measured fasting levels of various polyols in a large clinical cohort of cardiovascular patients and found that some candidate polyols are related to a higher risk of cardiovascular complications and death. In vitro data using human platelets revealed that the polyols xylitol and erythritol at the levels observed in fasting patients induce platelet aggregation potential. The investigator's data shows that erythritol and xylitol impact platelet function and may, therefore, contribute to cardiovascular mortality.
In preliminary studies the investigators found that when ingesting either erythritol or xylitol, the levels of these sweeteners in the plasma rise within the first hour after consumption. With this study the investigators wish to examine whether the postprandial levels are capable of altering platelet function in vitro. The investigators hypothesize that postprandial polyol concentrations following ingestion increase platelet aggregation in the blood.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Timothy Engelman, LPN
- Phone Number: 216-636-6153
- Email: engelmt@ccf.org
Study Contact Backup
- Name: Jennifer Wilcox, BA
- Phone Number: 216-636-6153
- Email: kirsopj@ccf.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Cohort 1 Inclusion Criteria:
- Age 18 years or above.
- Willing and able to sign the consent form.
Cohort 1 Exclusion Criteria:
- Use of anti-platelet medications within 14 days of study enrollment.
- Active infection or received antibiotics within 1 month of study enrollment.
- Use of over-the-counter probiotic within 1 month of study enrollment.
- Diabetes mellitus
- Ulcerative colitis, Crohn's disease, or other chronic gastrointestinal disorder.
- Past history of bariatric procedures or surgeries (e.g. gastric banding or bypass).
- Pregnancy.
- Significant chronic illness.
Cohort 2 Inclusion Criteria:
- Men and women age 18 years or above.
- Able to provide informed consent and comply with study protocol.
- Diabetes Mellitus Type II
Cohort 2 Exclusion Criteria:
- Use of anti-platelet medications within 14 days of study enrollment.
- Active infection or received antibiotics within 1 month of study enrollment.
- Use of over-the-counter probiotic within 1 month of study enrollment.
- Ulcerative colitis, Crohn's disease, or other chronic gastrointestinal disorder.
- Past history of bariatric procedures or surgeries (e.g. gastric banding or bypass).
- Pregnancy.
- Any condition that, in the judgment of the Investigator, would place a subject at undue risk by being enrolled in the trial or cause inability to comply with the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Xylitol, 30g
oral xylitol, a potent artificial sweetener
|
Intervention is a drink consisting of 300mL of water containing 30g of xylitol as a single oral dose.
|
Experimental: Erythritol, 30g
oral erythritol, a potent artificial sweetener
|
Intervention is a drink consisting of 300mL of water containing 30g of erythritol as a single oral dose.
|
Experimental: Xylitol, 5g
oral xylitol, a potent artificial sweetener
|
Intervention is a drink consisting of 300mL of water containing 5g of xylitol as a single oral dose.
|
Active Comparator: Glucose, 30g
oral glucose, delivered as dextrose
|
Intervention is a drink consisting of 300mL of water containing 30g of glucose (dextrose) as a single oral dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Platelet Aggregation After Polyol Ingestion
Time Frame: 30 minutes
|
Measuring platelet function 30 minutes after polyol ingestion, using established in vitro platelet assays.
|
30 minutes
|
Change from Baseline in Platelet Aggregation at 30 minutes Post Polyol Ingestion
Time Frame: Baseline and 30 minutes post ingestion of polyol intervention
|
Measuring changes in platelet function before versus after xylitol or erythritol ingestion, using established in vitro platelet assays.
|
Baseline and 30 minutes post ingestion of polyol intervention
|
Plasma Polyol Levels After Polyol Ingestion
Time Frame: 30 minutes
|
Measuring plasma levels of polyols 30 minutes after xylitol or erythritol ingestion, using established techniques by mass spectrometry.
|
30 minutes
|
Change from Baseline in Plasma Polyol levels at 30 minutes Post Polyol Ingestion
Time Frame: Baseline and 30 minutes post ingestion of polyol intervention
|
Measuring changes in levels of plasma polyols before versus after xylitol or erythritol ingestion, using established techniques by mass spectrometry.
|
Baseline and 30 minutes post ingestion of polyol intervention
|
Urinary Polyol levels After Polyol Ingestion
Time Frame: 30 minutes
|
Measuring the plasma levels of polyols 30 minutes after xylitol or erythritol ingestion, using established techniques by mass spectrometry.
|
30 minutes
|
Change from Baseline in Urinary Polyol Levels at 30 minutes Post Polyol Ingestion
Time Frame: Baseline and 30 minutes post ingestion of polyol intervention
|
Measuring changes in levels of urinary polyols before versus after xylitol or erythritol ingestion, using established techniques by mass spectrometry.
|
Baseline and 30 minutes post ingestion of polyol intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Plasma Lipid Profile at 30 minutes Post Polyol Ingestion
Time Frame: Baseline and 30 minutes post ingestion of polyol intervention
|
Measuring changes in lipid levels as markers of changes in metabolism before versus after xylitol or erythritol ingestion.
|
Baseline and 30 minutes post ingestion of polyol intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Wilson Tang, MD, The Cleveland Clinic
Publications and helpful links
General Publications
- Makinen KK. Gastrointestinal Disturbances Associated with the Consumption of Sugar Alcohols with Special Consideration of Xylitol: Scientific Review and Instructions for Dentists and Other Health-Care Professionals. Int J Dent. 2016;2016:5967907. doi: 10.1155/2016/5967907. Epub 2016 Oct 20.
- Oku T, Okazaki M. Laxative threshold of sugar alcohol erythritol in human subjects. Nutrition Research. 1996;16(4):577-89.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Risk Factor
-
University of Southern DenmarkRegion of Southern Denmark; Odense Patient Data Explorative Network; ENIGMA Solutions... and other collaboratorsActive, not recruitingCardiovascular Risk Factor | Risk CommunicationDenmark
-
University of Split, School of MedicineCompletedCardiovascular Risk Factor | Lifestyle Risk ReductionCroatia
-
University Hospital, BrestRecruiting
-
University Hospitals Cleveland Medical CenterRecruitingCardiovascular Risk FactorUnited States
-
Northwestern UniversityNorthShore University HealthSystem; Case Western Reserve University; Shirley... and other collaboratorsCompleted
-
University of ArizonaTerminatedCardiovascular Risk FactorUnited States
-
Penn State UniversityCompletedCardiovascular Risk FactorUnited States
-
Clinique BizetCompleted
-
University Hospital, BrestCompleted
-
University of DelawareCompleted
Clinical Trials on xylitol, 30g
-
Université de SherbrookeCompleted
-
Cairo UniversityUnknown
-
University Hospital, Basel, SwitzerlandCompletedPhysiological Satiation MechanismsSwitzerland
-
Oral Care Research Associates, SeattleUnknown
-
Hadassah Medical OrganizationUnknown
-
Children's Hospital Medical Center, CincinnatiTerminatedAllogeneic Hematopoietic Cell TransplantationUnited States
-
Baylor College of MedicineCompletedPreterm Birth | Periodontal Disease | Caries, DentalUnited States
-
Rambam Health Care CampusCarmel Medical CenterCompleted
-
Boston Children's HospitalNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedAcute Otitis MediaUnited States
-
University of WashingtonCompleted